Prostate apoptosis response gene-4 (par-4) abrogates the survival function of p185BCR-ABL in hematopoietic cells

Experimental Hematology

Volumn 32, Issue 7, 2004, Pages 649-656

  Kukoc Zivojnov, Natasa ^a   Puccetti, Elena ^a   Chow, Kai U ^a   Bergmann, Marion ^a   Ruthardt, Martin ^a   Hoelzer, Dieter ^a   Mitrou, Paris S ^a   Weidmann, Eckhart ^a   Boehrer, Simone ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; PROTEIN P185; RAS PROTEIN;

ACUTE LEUKEMIA; APOPTOSIS; ARTICLE; BIOTRANSFORMATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MEDICAL ASSESSMENT; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SOLID TUMOR; STEM CELL;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARRIER PROTEINS; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; CLONING, MOLECULAR; COLONY-FORMING UNITS ASSAY; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELLS; HUMANS; INTERLEUKIN-3; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MICE; PROSTATE; RATS; TRANSFECTION;

EID: 3042747499     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2004.04.004     Document Type: Article

References (48)

1. Faderl S., Kantarjian H.M., Thomas D.A., et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma. 36:2000;263-273
2. McLaughlin J., Chianese E., Witte O.N. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci U S A. 84:1987;6558-6562
3. Schimmer A.D., Hedley D.W., Penn L.Z., Minden M.D. Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view. Blood. 98:2001;3541-3553
4. Cirinna M., Trotta R., Salomoni P., et al. Bcl-2 expression restores the leukemogenic potential of a BCR/ABL mutant defective in transformation. Blood. 96:2000;3915-3921
5. Carlesso N., Frank D.A., Griffin J.D. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med. 183:1996;811-820
6. Frank D.A., Varticovski L. BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. Leukemia. 10:1996;1724-1730
7. Ilaria R.L. Jr., Van Etten R.A. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 271:1996;31704-31710
8. Nieborowska-Skorska M., Wasik M.A., Slupianek A., et al. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med. 189:1999;1229-1242
9. Varticovski L., Daley G.Q., Jackson P., Baltimore D., Cantley L.C. Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol Cell Biol. 11:1991;1107-1113
10. Skorski T., Kanakaraj P., Nieborowska-Skorska M., et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood. 86:1995;726-736
11. Skorski T., Bellacosa A., Nieborowska-Skorska M., et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 16:1997;6151-6161
12. Cortez D., Stoica G., Pierce J.H., Pendergast A.M. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. Oncogene. 13:1996;2589-2594
13. Cortez D., Kadlec L., Pendergast A.M. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol. 15:1995;5531-5541
14. Wong S., McLaughlin J., Cheng D., Witte O. Cell context specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors. Blood. 9:2003;9
15. Oki S., Limnander A., Danial N.N., Rothman P.B. Functional involvement of Akt signaling downstream of Jak1 in v-Abl-induced activation of hematopoietic cells. Blood. 100:2002;966-973
16. Sanchez-Garcia I., Grutz G. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci U S A. 92:1995;5287-5291
17. Boehrer S., Chow K.U., Puccetti E., et al. Deregulated expression of prostate apoptosis response gene-4 in less differentiated lymphocytes and inverse expressional patterns of par-4 and bcl-2 in acute lymphocytic leukemia. Hematol J. 2:2001;103-107
18. Nalca A., Qiu S.G., El-Guendy N., Krishnan S., Rangnekar V.M. Oncogenic Ras sensitizes cells to apoptosis by Par-4. J Biol Chem. 274:1999;29976-29983
19. Barradas M., Monjas A., Diaz-Meco M.T., Serrano M., Moscat J. The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression. EMBO J. 18:1999;6362-6369
20. Boehrer S., Chow K.U., Beske F., et al. In lymphatic cells par-4 sensitizes to apoptosis by down-regulating bcl-2 and promoting disruption of mitochondrial membrane potential and caspase activation. Cancer Res. 62:2002;1768-1775
21. Daley G.Q., Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci U S A. 85:1988;9312-9316
22. Pendergast A.M., Gishizky M.L., Havlik M.H., Witte O.N. SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence. Mol Cell Biol. 13:1993;1728-1736
23. Grignani F., Kinsella T., Mencarelli A., et al. High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res. 58:1998;14-19
24. Buettner R., Mora L.B., Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 8:2002;945-954
25. Sillaber C., Gesbert F., Frank D.A., Sattler M., Griffin J.D. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood. 95:2000;2118-2125
26. de Groot R.P., Raaijmakers J.A., Lammers J.W., Jove R., Koenderman L. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood. 94:1999;1108-1112
27. Coffer P.J., Koenderman L., de Groot R.P. The role of STATs in myeloid differentiation and leukemia. Oncogene. 19:2000;2511-2522
28. Lin T.S., Mahajan S., Frank D.A. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene. 19:2000;2496-2504
29. Neshat M.S., Raitano A.B., Wang H.G., Reed J.C., Sawyers C.L. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3- kinase and Raf. Mol Cell Biol. 20:2000;1179-1186
30. Bedi A., Barber J.P., Bedi G.C., et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood. 86:1995;1148-1158
31. Bedi A., Zehnbauer B.A., Barber J.P., Sharkis S.J., Jones R.J. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood. 83:1994;2038-2044
32. Evans C.A., Owen-Lynch P.J., Whetton A.D., Dive C. Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells. Cancer Res. 53:1993;1735-1738
33. McGahon A., Bissonnette R., Schmitt M., et al. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood. 83:1994;1179-1187
34. McGahon A.J., Nishioka W.K., Martin S.J., et al. Regulation of the Fas apoptotic cell death pathway by Abl. J Biol Chem. 270:1995;22625-22631
35. Nishii K., Kabarowski J.H., Gibbons D.L., et al. ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. Oncogene. 13:1996;2225-2234
36. Gelfanov V.M., Burgess G.S., Litz-Jackson S., et al. Transformation of interleukin-3-dependent cells without participation of Stat5/bcl-xL: cooperation of akt with raf/erk leads to p65 nuclear factor kappaB-mediated antiapoptosis involving c-IAP2. Blood. 98:2001;2508-2517
37. Goga A., McLaughlin J., Afar D.E., Saffran D.C., Witte O.N. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell. 82:1995;981-988
38. Pendergast A.M., Quilliam L.A., Cripe L.D., et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 75:1993;175-185
39. Sawyers C.L., McLaughlin J., Witte O.N. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med. 181:1995;307-313
40. Vaux D.L., Cory S., Adams J.M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 335:1988;440-442
41. Bissonnette R.P., Echeverri F., Mahboubi A., Green D.R. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature. 359:1992;552-554
42. Fanidi A., Harrington E.A., Evan G.I. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature. 359:1992;554-556
43. Eischen C.M., Roussel M.F., Korsmeyer S.J., Cleveland J.L. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol Cell Biol. 21:2001;7653-7662
44. Askew D.S., Ashmun R.A., Simmons B.C., Cleveland J.L. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene. 6:1991;1915-1922
45. Evan G.I., Wyllie A.H., Gilbert C.S., et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 69:1992;119-128
46. Packham G., Cleveland J.L. c-Myc and apoptosis. Biochim Biophys Acta. 1242:1995;11-28
47. Eischen C.M., Weber J.D., Roussel M.F., Sherr C.J., Cleveland J.L. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 13:1999;2658-2669
48. Schmitt C.A., McCurrach M.E., de Stanchina E., Wallace-Brodeur R.R., Lowe S.W. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13:1999;2670-2677